Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Adenocarcinoma of Lung 1

Interventions

Carboplatin 6Radiotherapy 5Radiation 4Nivolumab 4Magnetic Resonance Spectroscopy 4Specimen Handling 3Pemetrexed 3Biopsy 3Bevacizumab 3capmatinib 2Radiotherapy, Conformal 2Platinum 2Paclitaxel 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cisplatin 2CTLA-4 Antigen 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1osimertinib 1methoxyamine 1lazertinib 1fludarabine phosphate 1durvalumab 1defactinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × lazertinib × 90 days × Clear all
NCT04248829 2026-05-28

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Yuhan Corporation

Phase 3 Completed
393 enrolled 13 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡